Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
24.58
-1.79 (-6.79%)
At close: Sep 9, 2026, 4:00 PM EDT
25.60
+1.02 (4.15%)
Pre-market: Sep 10, 2026, 8:00 AM EDT
Maze Therapeutics Employees
Maze Therapeutics had 141 employees as of December 31, 2025. The number of employees increased by 16 or 12.80% compared to the previous year.
Employees
141
Change (1Y)
16
Growth (1Y)
12.80%
Revenue / Employee
$141,844
Profits / Employee
-$947,447
Market Cap
1.37B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 141 | 16 | 12.80% |
| Dec 31, 2024 | 125 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| Replimune Group | 465 |
| Innoviva | 159 |
| Absci | 140 |
| Cullinan Therapeutics | 109 |
| ArriVent BioPharma | 77 |
| Vor Biopharma | 76 |
| Savara | 70 |
MAZE News
- 22 hours ago - Maze Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 8 days ago - Maze Therapeutics to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 27 days ago - Maze Therapeutics Announces Appointments to Its Board of Directors - GlobeNewsWire
- 4 weeks ago - Maze Therapeutics reports Q2 EPS (76c), consensus (70c) - TheFly
- 4 weeks ago - Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights - GlobeNewsWire
- 4 weeks ago - Maze Therapeutics Earnings release: Q2 2026 - Filings
- 4 weeks ago - Maze Therapeutics Quarterly report: Q2 2026 - Filings
- 3 months ago - Maze Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts